Highlights from 2013 ICAAC, IDWeek, and EACS Meetings
- Details
- Category: HIV Treatment
- Created on Tuesday, 28 January 2014 00:00
Latest Positive Pulse Newsletter
In this overview Paul Sax from Harvard Medical School and Mark Sulkowski from Johns Hopkins discuss selected highlights from this fall's Interscience Conference on Microbial Agents and Chemotherapy (ICAAC), IDWeek, and the European AIDS Conference. The newsletter is available to all for free, with continuing medical education (CME) credit available for physicians and nurses.
ICAAC 2013: Stribild Is Effective and Well-tolerated in Older People with HIV
- Details
- Category: HIV Treatment
- Created on Tuesday, 01 October 2013 00:00
The Stribild single-tablet regimen matched both Atripla and boosted atazanavir (Reyataz) in efficacy among people age 50 and older, who responded as well as younger patients, researchers reported at the recent 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy in Denver. Related studies showed that Stribild had durable efficacy through 3 years and caused fewer central nervous system (CNS) side effects than Atripla.
Coverage of 2013 Interscience Conference on Antimicrobial Agents and Chemotherapy
- Details
- Category: HIV Treatment
- Created on Friday, 13 September 2013 00:00
HIVandHepatitis.com coverage of the 53nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Denver, September 9-13, 2013.
Highlights of this year's meeting include experimental antiretroviral drugs and treatment strategies, CD4 cell gene therapy, HIV/HCV coinfection, liver transplants for people with HIV, and other sexually transmitted infections.
HIVandHepatitis.com ICAAC 2013 conference section
9/13/13
ICAAC 2013: New Integrase Inhibitor GSK1265744 Safe and Well-tolerated in 8 Studies
- Details
- Category: HIV Treatment
- Created on Tuesday, 01 October 2013 00:00
The investigational HIV integrase inhibitor GSK1265744 was well tolerated with no notable safety concerns in a meta-analysis of 8 studies testing the drug as either a pill or a long-acting injection, researchers reported at the recent 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013) in Denver.
ICAAC Underway This Week in Denver
- Details
- Category: HIV Treatment
- Created on Wednesday, 11 September 2013 00:00
The 53nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013) kicked off Tuesday and runs throughout the week in Denver. HIVandHepatitis.com will be on site to cover the latest research on HIV and hepatitis B and C.
More Articles...
- ICAAC 2013: Single-tablet Regimen Improves ART Adherence and Reduces Hospitalization
- ICAAC 2013: Dolutegravir Shows Good Efficacy Across Patient Groups
- ICAAC 2013: Researchers Present Data on New NNRTIs AIC292 and MK-1439
- ICAAC 2013: New Tenofovir Formulation Has Less Effect on Kidneys and Bones
- ICAAC 2013: CD4 Cell Gene Therapy May Enable Functional Control of HIV Off Treatment
- ICAAC 2013: Tenofovir Vaginal Ring Protects Monkeys on Depo-Provera Against HIV-like Virus
- ICAAC 2013: Many Truvada PrEP Users Are Women and Young People, Survey Finds
- ICAAC 2013: Risk Factors and Screening for HPV Anal Dysplasia
- ICAAC 2013: Raltegravir Safest for HIV+ Patients on Cancer Chemotherapy
- ICAAC 2013: Raltegravir Appears Safe for Mothers and Babies During Pregnancy
- ICAAC 2013: Liver Cancer Often Diagnosed Late with Poor Survival in People with HIV
- ICAAC 2013: Is HCV Infection Increasing Among HIV+ Gay Men in Japan?
- ICAAC 2013: Treatment of HCV Genotypes 2/3 in HIV/HCV Coinfected People
- ICAAC 2013: Interferon Response Reduces Liver Disease and Death in HIV/HCV Coinfected
- ICAAC 2013: Novel Therapeutic Vaccine Reduces Genital Herpes Shedding
Web Design and Development by